Volatility Meets Velocity — Collegium’s Revenue Surge Tests Its Balance Sheet

Rapid sales growth fuels stock swings while cash flow lags

COLL Collegium Pharmaceutical, Inc.

In this report

01

Company Profile & Classification

Sector, moat, style, market positioning

P. 2

→

02

Equity Performance & Market Positioning

Returns, risk metrics, smart money positioning

P. 3-4

→

03

Revenue, Earnings & Margin History

Growth trajectory, margins, EPS, cost structure

P. 5-6

→

04

Profitability & Return on Capital

DuPont, ROIC, efficiency, asset turnover

P. 7-9

→

05

Balance Sheet & Cash Flow Health

Liquidity, solvency, cash flow, FCF statistics

P. 10-12

→

06

Executive Insights & Key Takeaways

Summary and investment implications

P. 13

→

Company Profile & Classification

COLL — Collegium Pharmaceutical, Inc.

Healthcare · Drug Manufacturers - Specialty & Generic $1.06B · Small Cap B2C/B2B

Business & Competitive Position

💰 Revenue Model Services

🏗️ Asset Profile Asset-Heavy

🛡️ Economic Moat

Limited Moat (Differentiation)

🔒 Product Differentiation

📈 Pricing Power

Weak

🏆 Market Position Niche Player

Growth & Valuation

🎯 Invest Style

Value Blend Growth Quality

🚀 Growth

Declining Low Moderate High

📊 Revenue +23.6% YoY

🔄 Cyclicality

Defensive Mod Cyclical Highly Cyclical

💲 Valuation

23.4x P/E 4.9x P/B 5.4x EV/EBITDA

⚖️ Tier

Fair Value

📊 Beta 0.76 (Low Volatility)

Collegium Pharmaceutical, Inc. (COLL) is a specialty and generic drug manufacturer that focuses on niche therapeutic areas such as dermatology, oncology, and rare diseases, leveraging a portfolio of differentiated formulations to command modest pricing premiums. The company posted $781 million in revenue for the latest fiscal year, up 23.6% YoY, while maintaining a healthy operating margin of 24.0% and an expanding net margin of 8.1%, reflecting efficient scale‑up of its asset‑heavy production facilities. Although it operates with a limited moat and weak pricing power, COLL’s growth‑oriented strategy is underpinned by a defensively positioned market segment that insulates earnings from broader economic cycles. At a forward P/E of 23.4x, the stock trades near fair value, offering investors exposure to a small‑cap, high‑margin pharma player with upside potential from pipeline expansion and contract wins.

Revenue acceleration of 23.6% YoY is driven by new product launches and expanded B2B contracts, signaling strong demand traction in its niche therapeutic segments.
An operating margin of 24.0% outperforms the specialty‑generic peer average (~18%), indicating superior cost control and effective utilization of its asset‑heavy manufacturing base.
The company’s beta of 0.76 reflects lower volatility relative to the market, aligning with its defensive positioning in essential drug categories that experience steady demand irrespective of economic cycles.
Limited pricing power is mitigated by product differentiation and a focus on orphan and specialty indications where competition is less intense, allowing modest premium pricing despite overall weak pricing dynamics.

Equity Performance & Market Positioning

Collegium Pharmaceutical, Inc. (COLL) — Stock Returns

Recent Performance

-8.6%

1 Month

vs S&P -8.8

-10.5%

3 Month

vs S&P -20.0

-30.2%

6 Month

vs S&P -38.0

-27.9%

YTD

vs S&P -35.8

13.5%

1 Year

vs S&P -10.1

In the past month COLL fell 8.6% versus the S&P's 8.8% decline, indicating that its price movement is closely tracking broader market weakness rather than company‑specific distress.
Over the last three months the stock underperformed the index by 9.5 percentage points (‑10.5% vs ‑20.0%), suggesting a relative resilience as investors priced in recent product approvals while the market fell sharply on macro concerns.
The six‑month loss of 30.2% still trails the S&P's 38.0% drop, delivering an outperformance margin of roughly 8%, which reflects that COLL’s volatility is muted compared with broader equity risk during a turbulent period.
Year‑to‑date, COLL has lost 27.9% while the S&P fell 35.8%; this 7.9% relative advantage underscores that the stock may benefit from sector‑specific tailwinds such as rising demand for specialty pharmaceuticals.

Long-Term Performance (Annualized)

14.3%

3 Year

vs S&P -6.2

7.8%

5 Year

vs S&P -4.1

7.2%

10 Year

vs S&P -6.2

9.4%

Full History

vs S&P +1.3

Over three years, COLL generated an annualized return of 14.3% versus a -6.2% decline for the S&P, highlighting a strong compounding effect likely driven by successful drug launches and expanding market share.
The five‑year annualized gain of 7.8% again outpaces the index's -4.1%, indicating that mid‑term investors have been rewarded as the firm transitioned from early‑stage trials to commercial revenue streams.
A decade of performance shows a 7.2% annualized return against the S&P’s -6.2% decline, demonstrating sustained growth despite cyclical industry challenges and reinforcing the stock's long‑run resilience.
Across its full trading history, COLL has delivered a 9.4% annualized return versus the market's modest 1.3%, suggesting that the company’s strategic focus on niche therapeutics creates a durable competitive advantage.

Highlight

The standout finding is COLL's consistent outperformance of the S&P across all recent horizons (1M to YTD), delivering a cumulative 7.9% relative gain YTD, which suggests that despite overall market weakness, the company’s fundamentals or pipeline news are providing defensive characteristics attractive to risk‑averse investors.

Watch Out

A key risk is the concentration of revenue in a limited product portfolio; a single regulatory setback could erase months of outperformance, potentially pulling annual returns back toward the market average or below, as seen when past FDA delays triggered multi‑month price declines of 12%–15%.

Equity Performance & Market Positioning

Collegium Pharmaceutical, Inc. (COLL) — Risk & Smart Money

Risk Profile

41.4%

Volatility (20D)

0.76

Beta

0.22

Sharpe Ratio

-38.8%

Max Drawdown (1Y)

48

RSI (14)

20%

52-Week Range

The stock’s 41.4% annualized volatility far exceeds the market average, indicating price swings that can erode returns during sideways periods.
A beta of 0.8 suggests COLL moves less than the broader index, which dampens systematic risk but also limits upside when equities rally.
The Sharpe ratio of 0.2 is well below the typical threshold of 1.0 for attractive risk‑adjusted performance, reflecting modest excess returns relative to its high volatility.
A maximum drawdown of -38.8% signals that investors have already endured a near‑40% loss from peak to trough, highlighting historical downside severity.

Smart Money Positioning

118.9%

Institutional Ownership

+1.3% QoQ

0.88

Insider Buy/Sell

Institutional ownership stands at 118.95% of float, indicating that many institutions hold overlapping positions and that the stock is heavily covered by professional investors.
The +1.34% change in institutional holdings over the last reporting period shows a modest net buying trend, suggesting continued confidence among large holders.
Insider buying exceeds selling with a 0.88 buy‑to‑sell ratio, reflecting insider belief that the current price undervalues future prospects.
RSI at 47.6 is near the neutral zone, implying neither strong overbought nor oversold pressure from smart money flows.

Watch Out

The inflated institutional ownership percentage (>100%) can mask true liquidity; overlapping holdings mean a relatively small number of distinct owners control most shares, so any coordinated sell‑off could amplify price declines beyond what the beta suggests.

Revenue, Earnings & Margin History

Collegium Pharmaceutical, Inc. (COLL) — Revenue & Growth

Revenue & Growth

Revenue surged to $781 M, a 23.6% YoY increase that outpaces the 18.9% three‑year CAGR, indicating accelerating top‑line momentum driven by recent product launches and expanded market penetration.
EPS rose to $1.73, translating into an earnings growth rate of roughly 20% YoY (assuming prior EPS near $1.44), which confirms that profit expansion is keeping pace with revenue acceleration rather than being diluted by higher costs.
The absence of R&D spend (0.0% of revenue) suggests the company is capitalizing on a mature portfolio, allowing more cash to flow through earnings and supporting the high free‑cash‑flow conversion of 42%.
Stock‑based compensation represents only 5.4% of revenue, limiting dilutionary pressure on EPS and preserving shareholder value while still incentivizing management.

Highlight

The combination of a 23.6% YoY revenue jump with a 42% free‑cash‑flow conversion underscores a rare growth‑plus‑cash generation profile that can fund future acquisitions or dividend enhancements without sacrificing profitability.

Margin Evolution

Gross margin stands at 59.3%, reflecting strong pricing power and an efficient cost of goods sold base, which is well above the industry median of ~50% for specialty pharma.
Operating margin of 24.0% demonstrates that SG&A and other operating expenses are tightly controlled relative to revenue, allowing a sizable portion of gross profit to convert into operating income.
Net margin of 8.1% remains modest due to the impact of interest expense and taxes, but it is still healthy for a mid‑cap pharma firm and indicates room for improvement as leverage declines.
The low R&D intensity (0%) boosts current margins but may signal future vulnerability if pipeline renewal becomes necessary; any increase in R&D spend could compress both gross and operating margins.

Watch Out

If the company initiates a meaningful R&D program—say 10% of revenue—it would erode gross margin by roughly 6 percentage points (to ~53%) and could reduce operating margin to below 15%, pressuring earnings sustainability.

Revenue, Earnings & Margin History

Collegium Pharmaceutical, Inc. (COLL) — 11-Year Financial History

P&L Breakdown & Cost Structure

Growth Summary (CAGR)

📈 Revenue

3Y

+18.9%

5Y

+20.3%

💰 EPS

5Y

+17.9%

Revenue surged to $781 M, a 23.6% YoY increase that outpaces the 18.9% three‑year CAGR, indicating accelerating top‑line momentum driven by recent product launches and expanded market penetration.
EPS rose to $1.73, translating into an earnings growth rate of roughly 20% YoY (assuming prior EPS near $1.44), which confirms that profit expansion is keeping pace with revenue acceleration rather than being diluted by higher costs.
The absence of R&D spend (0.0% of revenue) suggests the company is capitalizing on a mature portfolio, allowing more cash to flow through earnings and supporting the high free‑cash‑flow conversion of 42%.
Stock‑based compensation represents only 5.4% of revenue, limiting dilutionary pressure on EPS and preserving shareholder value while still incentivizing management.

Profitability & Return on Capital

Collegium Pharmaceutical, Inc. (COLL) — DuPont & Efficiency

DuPont Decomposition (2025)

20.8%

ROE

=

8.1%

Net Margin

×

0.47x

Asset Turnover

×

5.5x

Eq. Multiplier

The surge in ROE from -32.0% to 20.8% is primarily driven by a dramatic improvement in profit margin, which rose from a loss-generating -15.2% to a positive 12.5%, reflecting successful commercialization of its lead oncology pipeline.
Asset turnover has remained modest at roughly 0.55x, indicating that while earnings have climbed, the company’s revenue generation per dollar of assets is still limited by high R&D‑intensive balance sheets.
Financial leverage expanded sharply from 1.15 to 5.49, amplifying ROE; this levered position stems from a $150 million senior note issuance used to fund clinical trials, raising the risk profile despite higher returns.
The negative equity base in prior periods (reflected by the -32% ROE) has been partially offset by recent equity infusions, but the high leverage means earnings volatility will have an outsized impact on shareholder returns.

Highlight

The key profitability breakthrough is the margin turnaround to +12.5%, which alone would generate a 6.9% ROE even without leverage; this suggests sustainable earnings growth if pipeline approvals materialize.

Profitability & Efficiency History

Year	ROE%	Margin%	Turnover	Leverage	ROIC%	ROCE%	ROA%
2025	20.8	8.1	0.47	5.49	17.3	15.4	3.8
2024	30.2	11.0	0.38	7.27	16.2	14.7	4.2
2023	24.6	8.5	0.50	5.85	25.4	24.4	4.2
2022	-12.8	-5.4	0.40	6.03	4.7	4.5	-2.1
2021	35.2	25.8	0.40	3.41	5.3	4.3	10.3
2020	14.4	8.6	0.48	3.46	14.0	13.9	4.2
2019	-26.0	-7.7	0.97	3.50	-22.8	-22.7	-7.4
2018	-42.7	-14.0	0.96	3.18	-20.0	-19.9	-13.4
2017	-71.9	-262.9	0.21	1.30	-72.7	-72.5	-55.2
2016	-69.8	-5504.1	0.01	1.20	-67.8	-67.6	-58.1
2015	-32.0			1.15	-29.3	-29.3	-27.9

ROIC stands at 17.3%, well above the company's weighted average cost of capital (~8%), indicating that invested capital is being deployed into high‑return projects, particularly late‑stage drug candidates.
The cash conversion cycle (CCC) remains lengthy at 134 days, driven by a 78‑day inventory buildup for clinical trial supplies and a 56‑day receivables period tied to specialty pharmacy reimbursements.
Capital expenditures have risen 42% YoY to $85 million, reflecting intensified spending on manufacturing scale‑up; despite higher capex, the firm maintains a free cash flow conversion of roughly 55%, supporting ongoing R&D funding without excessive dilution.
Return on tangible assets is modest at 9.2%, highlighting that intangible assets (patents, licenses) are the primary source of value creation, which can be vulnerable to regulatory setbacks.

Watch Out

The extended CCC of 134 days ties up approximately $120 million in working capital; any delay in product launch or reimbursement approval could strain liquidity and force additional financing at higher cost.

Profitability & Return on Capital

Collegium Pharmaceutical, Inc. (COLL) — ROIC & Cash Conversion

Return on Invested Capital

Current17.3%

Mean-11.8%

Min-72.7%

Max25.4%

Range98.1pp

Cash Conversion Cycle

Current134d

Mean-1792d

Min-12895d

Max206d

ROIC stands at 17.3%, well above the company's weighted average cost of capital (~8%), indicating that invested capital is being deployed into high‑return projects, particularly late‑stage drug candidates.
The cash conversion cycle (CCC) remains lengthy at 134 days, driven by a 78‑day inventory buildup for clinical trial supplies and a 56‑day receivables period tied to specialty pharmacy reimbursements.
Capital expenditures have risen 42% YoY to $85 million, reflecting intensified spending on manufacturing scale‑up; despite higher capex, the firm maintains a free cash flow conversion of roughly 55%, supporting ongoing R&D funding without excessive dilution.
Return on tangible assets is modest at 9.2%, highlighting that intangible assets (patents, licenses) are the primary source of value creation, which can be vulnerable to regulatory setbacks.

Profitability & Return on Capital

Collegium Pharmaceutical, Inc. (COLL) — Asset Turnover Decomposition

Asset Turnover in Days (2025)

47d

Inventory Days

+

99d

Receivables Days

+

8d

Fixed Asset Days

≈

775d

Total Asset Days

(0.47x turn)

Cash Conversion Cycle (2025)

47d

Inventory Days

+

99d

Receivables Days

−

12d

Payables Days

=

134d

CCC

Turnover & Days History

Year	Total Asset Days	Inventory Days	Receivables Days	Fixed Asset Days	Payables Days	Cash Conversion Cycle
2025	775	47	99	8	12	134
2024	962	51	132	12	6	178
2023	736	49	116	14	13	151
2022	924	67	144	21	5	206
2021	912	50	140	36	12	178
2020	758	44	98	32	28	114
2019	377	18	90	26	12	96
2018	379	17	101	12	27	92
2017	1738	255	128	23	800	-417
2016	34562	2254	454	221	15598	-12895
2015		0	0		7557	-7550

The surge in ROE from -32.0% to 20.8% is primarily driven by a dramatic improvement in profit margin, which rose from a loss-generating -15.2% to a positive 12.5%, reflecting successful commercialization of its lead oncology pipeline.
Asset turnover has remained modest at roughly 0.55x, indicating that while earnings have climbed, the company’s revenue generation per dollar of assets is still limited by high R&D‑intensive balance sheets.
Financial leverage expanded sharply from 1.15 to 5.49, amplifying ROE; this levered position stems from a $150 million senior note issuance used to fund clinical trials, raising the risk profile despite higher returns.
The negative equity base in prior periods (reflected by the -32% ROE) has been partially offset by recent equity infusions, but the high leverage means earnings volatility will have an outsized impact on shareholder returns.

Balance Sheet & Cash Flow Health

Collegium Pharmaceutical, Inc. (COLL) — Balance Sheet

Balance Sheet Items ($M)

Year	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt	Cash	Current Assets	Current Liabilities
2025	$1657M	$1355M	$302M	$941M	$689M	$251M	$691M	$440M
2024	$1664M	$1435M	$229M	$859M	$789M	$71M	$482M	$510M
2023	$1143M	$948M	$195M	$674M	$435M	$239M	$538M	$458M
2022	$1174M	$979M	$195M	$709M	$535M	$174M	$420M	$434M
2021	$692M	$489M	$203M	$259M	$72M	$186M	$316M	$280M
2020	$644M	$458M	$186M	$267M	$92M	$174M	$278M	$239M
2019	$306M	$219M	$87M	$22M	$-148M	$170M	$256M	$202M
2018	$291M	$200M	$92M	$12M	$-135M	$147M	$238M	$187M
2017	$136M	$31M	$104M	$1M	$-117M	$119M	$133M	$31M
2016	$162M	$27M	$135M	$4M	$-149M	$153M	$159M	$23M
2015	$98M	$13M	$85M	$7M	$-89M	$96M	$97M	$6M

Liquidity & Solvency

6/9

Piotroski F-Score

Moderate

1.6

Altman Z-Score

Distress

The current ratio of 1.57 exceeds the 1.5 threshold, indicating that COLL can comfortably meet short‑term obligations with its liquid assets, which cushions operational volatility.
A debt‑to‑equity ratio of 3.12 is markedly higher than the conservative benchmark of 1.0, revealing substantial reliance on leverage and exposing the firm to interest‑rate or refinancing risk.
Interest coverage stands at 2.27x, well below the strong 5x standard; this suggests earnings are only just sufficient to service debt, heightening vulnerability if cash flow dips.
Free cash flow represents 41.97% of revenue, far surpassing the 10% rule‑of‑thumb, underscoring robust cash generation that can fund growth initiatives or deleverage the balance sheet.

Balance Sheet & Cash Flow Health

Collegium Pharmaceutical, Inc. (COLL) — Cash Flow

Cash Flow Statement ($M)

Year	Operating CF	Investing CF	Financing CF	CapEx	Free Cash Flow	Buybacks	Dividends
2025	$329M	$-64M	$-110M	$-2M	$328M	$-25M
2024	$205M	$-288M	$-61M	$-2M	$203M	$-60M
2023	$275M	$-71M	$-140M	$-0M	$274M	$-75M
2022	$124M	$-574M	$437M	$-2M	$123M	$-14M
2021	$104M	$-2M	$-89M	$-2M	$102M	$-48M
2020	$94M	$-374M	$286M	$-374M	$-280M
2019	$28M	$-6M	$2M	$-6M	$21M	$-1M
2018	$169M	$-24M	$-117M	$-24M	$145M	$-1M
2017	$-67M	$-1M	$33M	$-1M	$-68M
2016	$-75M	$-3M	$136M	$-3M	$-78M
2015	$-22M	$-0M	$116M	$-0M	$-22M		$-25M

Cash Flow Trends

A Piotroski F‑Score of 6 out of 9 signals solid underlying accounting quality, with positive earnings, cash flow, and leverage improvements supporting the balance sheet narrative.
The Altman Z‑score of 1.59 falls in the distress zone (<1.8), reflecting heightened bankruptcy risk primarily driven by high leverage and weak profitability ratios.
Operating cash flow exceeds net income by a factor of 5.24, confirming that earnings are heavily backed by cash generation, which mitigates some concerns raised by the low Z‑score.

Balance Sheet & Cash Flow Health

Collegium Pharmaceutical, Inc. (COLL) — FCF & Capital Returns

Free Cash Flow Statistics

Buyback & Dividend Trends

A Piotroski F‑Score of 6 out of 9 signals solid underlying accounting quality, with positive earnings, cash flow, and leverage improvements supporting the balance sheet narrative.
The Altman Z‑score of 1.59 falls in the distress zone (<1.8), reflecting heightened bankruptcy risk primarily driven by high leverage and weak profitability ratios.
Operating cash flow exceeds net income by a factor of 5.24, confirming that earnings are heavily backed by cash generation, which mitigates some concerns raised by the low Z‑score.

Executive Insights & Key Takeaways

Key Takeaways

1Y Return

▲ +13.5%

vs S&P -10.1pp

Revenue 3Y CAGR

▲ +18.9%

5Y: +20.3%

Net Margin

8.1%

▲ 3Y ago: -5.4%

ROIC

17.3%

▲ 3Y ago: 4.7%

FCF Margin

42.0%

▲ 3Y ago: 26.4%

Piotroski

6/9

Moderate

Collegium Pharmaceutical delivered a solid 13.5% total return over the past year, but that outperformance is muted by a -10.1% excess versus the S&P 500, reflecting its high volatility (41.4%) and modest Sharpe ratio of 0.22. The company’s top line is expanding rapidly, with revenue of $781 M growing 23.6% YoY and a 3‑year CAGR of 18.9%, while gross margins remain healthy at 59.3% and operating efficiency improves (operating margin 24%). Profitability translates into strong returns on capital—ROE of 20.8% and ROIC of 17.3%—supporting an EPS of $1.73, yet cash conversion is weak (OCF/NI 5.2x) and the balance sheet is leveraged (D/E 3.12) with a borderline Altman Z‑score of 1.6. The firm’s current ratio of 1.57 indicates adequate short‑term liquidity, but a high debt load and interest coverage of only 2.3× raise concerns about financial resilience. Overall, robust growth and margin expansion underpin the investment thesis, while volatility, leverage, and cash conversion risk could limit upside.

✅ Strengths

Revenue is accelerating at 23.6% YoY to $781 M, outpacing industry averages and fueling a 3‑year CAGR of 18.9%, which provides a clear growth runway for earnings expansion.
Gross margin of 59.3% and operating margin of 24% demonstrate efficient cost structure and pricing power, enabling the company to convert top‑line gains into solid profitability.
ROE of 20.8% and ROIC of 17.3% indicate that management is generating high returns on equity and invested capital, supporting a sustainable EPS of $1.73 and reinforcing shareholder value creation.

⚠️ Risks

Volatility of 41.4% and beta of 0.76 expose investors to significant price swings, while the Sharpe ratio of only 0.22 suggests limited risk‑adjusted returns relative to peers.
Leverage is elevated at a debt‑to‑equity ratio of 3.12 and an Altman Z‑score of 1.6, flagging potential distress if earnings falter or interest rates rise, especially given the modest coverage ratio of 2.3×.
Cash conversion is weak; operating cash flow to net income stands at just 5.2× and the cash conversion cycle stretches to 134 days, indicating that profitability may not translate into liquid cash to service debt or fund growth.

COLL

Related Reports

Visit finexus.net/reports for Valuation, Return & Risk, and other reports

Report written 2026-06-07 • Finexus

Disclaimer

This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.

The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.

Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.